Josh serves as President and Chief Executive Officer at Dyne Therapeutics. He was previously COO and CFO of Kaleido Biosciences leading the company through its initial IPO and its Phase 2 programme development. While serving as COO and CFO at Versartis, Josh spearheaded the finance strategy, its IPO and successful first product partnership. His previous roles include: EVP of Finance (Pharmacyclics); CFO (Zeltiq Aesthetics) and investment banking positions at Citigroup Global Markets Inc, and Morgan Stanley. Over the course of his career, Josh has raised nearly $2 billion in capital. He holds a B.A. in Business Administration from the University of Notre Dame.
Nicola Thompson PhD
Chief Executive Officer
Nicki has over 25 years’ experience in pharmaceutical and biotechnology R&D in a variety of senior scientific and leadership roles. She was previously VP and Global Head of External Drug Discovery at F. Hoffmann-La Roche Ltd and prior to that, Senior Director, Business Development for GSK’s Centre of Excellence for External Drug Discovery (CEEDD). Nicki’s Biotech experience includes her role as Chair of the Board for Nanna Therapeutics Ltd, founding CEO of VirionHealth and Head of Drug Discovery at Syntaxin Ltd. She holds a PhD in Cell Biology from University College London.
Christian Jung PhD
Christian joined SV Health Managers in 2019. He is a Partner in the Dementia Discovery Fund (DDF) and currently represents the fund on the Boards of Amphista Therapeutics Ltd., LoQus23 Therapeutics Ltd. and Transine Therapeutics Ltd. Prior to joining SV, Christian held roles with Wellington Partners Life Sciences and High-Tech Gründerfonds, Europe’s leading seed fund with € 1.3bn under management. There, Christian structured and completed the seed- and early-stage investments in nine life sciences companies, including Amal Therapeutics SA (acquired by Boehringer Ingelheim in 2019 for up to € 325m), Cunesoft GmbH (acquired by Phlexglobal in 2020 for an undisclosed amount) and Rigontec GmbH (acquired by MSD in 2017 for up to €464m).
Christian was awarded a PhD with distinction in Medical Science and Technology for his work on patient-specific induced pluripotent stem cells and obtained his MSc degree in Molecular Biotechnology, both from the Technical University of Munich. The key articles generated in the context of his PhD were published in the New England Journal of Medicine, EMBO Molecular Medicine and FASEB Journal and have so far been cited more than 1,000 times.
Stefan Luzi PhD
Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on venture and growth capital investments in the biopharmaceutical sector. He led several investments and currently represents Gilde on the boards of Amphista Therapeutics Ltd., Lava Therapeutics B.V. and Lumicks B.V.
Prior to joining Gilde, Stefan worked at Merck KGaA where he completed international assignments in the Global Business Intelligence and M Ventures divisions. Additionally, he was involved in various consulting projects spanning the pharmaceutical and chemical departments at Merck and co-moderated Merck Serono’s innovation competitions.
Stefan received a B.Sc. in Biology and M.Sc. in Biotechnology from the Swiss Federal Institute of Technology Zurich (ETH) and his MPhil in Bioscience Enterprise from the University of Cambridge. He completed his Ph.D. with Nobel Laureate Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge, where he developed a bicyclic peptide-based drug discovery platform.
Bart is a Managing Director at the Novartis Venture Fund and its Head of Transactions & Legal based in Basel, Switzerland. He currently serves on the board of Enterprise Therapeutics Holdings and UZH Life Sciences Fund and was previously on the board of Oculis (until its NASDAQ IPO), Inflazome (until it was acquired by Roche) and Enterprise Therapeutics (until its TMEM16A program was acquired by Roche).
Prior to joining NVF, Bart held various senior roles in Novartis’ Corporate Legal M&A and BD&L groups. Before joining Novartis in 2009, he was with the Investment Banking Division of Bank of America Merrill Lynch in New York and, before that, he was an attorney with the Corporate/M&A Group at the law firm of Allen & Overy LLP in New York. Bart holds Juris Doctor and Bachelor of Civil Law degrees from McGill Law School in Canada and is a member of the New York State Bar.
Rogier Rooswinkel PhD
Rogier is Partner at Forbion where he is responsible for evaluation and structuring of new investment opportunities across all disease areas with an emphasis on oncology. He currently serves as a board member for Amphista, Catalym and Achilles and as a board observer for Enterprise, Prilenia and Escalier
Prior to joining Forbion, Rogier worked as a post-doc at the Netherlands Cancer Institute (NKI), division of immunology. In 2013 he received his PhD degree Cum Laude from the University of Amsterdam for the work he performed at the NKI. Before that, he received a Master’s degree in Oncology at the VU university in Amsterdam, NL.
Dominic Schmidt PhD
Dominic joined Advent Life Sciences in April 2022 with a background in biochemistry, genomics, molecular oncology, strategy consulting and life science venture capital.
Prior to joining Advent, he spent eight years as a Partner in the investment team of Syncona, a publicly listed healthcare investment company. During his time there he was involved in the founding, funding and building of several life science businesses and served on the Boards of Anaveon, Orbit Biomedical (merged with Gyroscope), Gyroscope Therapeutics (acquired by Novartis for up to $1.5 billion), Purespring Therapeutics and Forcefield Therapeutics.
After gaining a German Diplom Degree in Biochemistry from the Free University of Berlin and the Max Planck Institute for Molecular Genetics he received a PhD from the Department of Oncology at the University of Cambridge. Dominic was a Cancer Research UK scholar and his research has been published in Cell, Nature and Science. His PhD thesis was recognized with the Pontecorvo and Science & SciLife Lab Prizes.